Cabozantinib plus nivolumab for kidney cancer with bone spread
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic clear cell kidney cancer (a common type) that has spread to a bone and also to another spot like an organ or soft tissue.
- You have not had cabozantinib (Cometriq) or nivolumab (Opdivo) before.
- You are able to have two biopsies (tissue samples) — one before starting the study drug and one after.
- You have good enough organ function, such as kidneys (GFR at least 30) and liver (blood tests within limits), and a performance status that lets you be up and around (ECOG 0-2).
- You do not have uncontrolled high blood pressure, major heart problems, or active bleeding risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
This study tests the drug cabozantinib in people with kidney cancer who are also on dialysis. It aims to see if the drug is safe and works for this group.
This trial is testing a combination of two drugs, cabozantinib and nivolumab, in people aged 70 or older who have advanced kidney cancer that hasn't been treated yet. The goal is to see if this combination works well and is safe for older patients.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.